ABIOMED Inc. Shares Close in on 52-Week High - Market Mover

The shares closed 0.2% below its 52-week high of $348.56, with trading volume higher than its 30 day average

Jan 22, 2021 by Kwhen Finance Editors

ABIOMED Inc. Shares Close in on 52-Week High - Market Mover
ABIOMED Inc. shares closed today at 0.2% below its 52 week high of $348.56, giving the company a market cap of $15B. The stock is currently up 7.3% year-to-date, up 88.6% over the past 12 months, and up 301.4% over the past five years. This week, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 1.9%.

Trading Activity

  • Trading volume this week was 3.2% lower than the 20-day average.
  • Beta, a measure of the stock’s volatility relative to the overall market stands at 0.7.

Technical Indicators

  • The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
  • MACD, a trend-following momentum indicator, indicates a downward trend.
  • The stock closed above its Bollinger band, indicating it may be overbought.

Fundamentals & Catalysts

  • Over the past 12 months the company generated $269 million in earnings before interest and taxes from $840 million in revenue. It currently holds $443 million in cash and $3 million in debt.
  • Its forward price-to-earnings (P/E) ratio of 0 is lower than its current P/E ratio of 75.65, implying that analysts are expecting an increase in earnings.
  • The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at -1.79. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
  • The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 0.01 which means it currently has $0.01 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
  • The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 13.14. This means that the stock is trading at a premium of 13 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
  • The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 16.65.
  • The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 16.14.

P/E

75.65

EBITDA

$269M

P/Book

13.14

Mkt Cap

$15B

P/Sales

16.65

Revenue

$840M

EPS (TTM)

4.56

PEG Ratio

-1.79

EV/Revenue

16.14

Total Cash

$443M

Debt/Equity

0.01

Forward P/E

0.00

Current Debt

$3M

Gross Profit

$689M

Dividend Date

-

Earnings Date

-

Profit Margin

0.24

Revenue/Share

18.67

Total Revenue

$840M

Enterprise Val

$13B

Put/Call Ratio

0.86

Revenue/Employee

547449.87

Market Comparative Performance

  • The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis
  • The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis
  • The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis
NameDoD %ΔYTD %Δ1 Yr %52-Week H %52-Week L %
ABIOMED Inc.-0.27.388.6-0.2166.6
Dow Jones Industrial Average-0.61.48.6-0.669.1
S&P 500 Index-0.42.417.6-0.573.6
Health Care-0.54.217.4-1.162.6

Peer Group Comparative Performance

  • The company's stock priceperformance year-to-date beats the peer average by 2708.8%
  • The company's stock price performance over the past 12 months beats the peer average by 854.9%
  • The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 1675.5% higher than the average peer.
NameMKT CAP (USD)P/EYTD %Δ1 Yr %Δ52-Week H %52-Week L %
ABIOMED Inc.ABMD75.77.388.6-0.2166.6
Peer AvgN/A4.30.39.3-9.8104.0
Boston Scientific CorporationBSX14.43.0-15.0-14.844.9
Teleflex IncorporatedTFX49.0-6.10.8-6.472.1
AtriCure Inc.ATRC06.157.5-4.0133.4
Stereotaxis Inc.STXS-46.3-2.0-6.2-14.1165.5

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?